Comparative Pharmacology
Head-to-head clinical analysis: ASACOL versus ROWASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL versus ROWASA.
ASACOL vs ROWASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asacol (mesalamine) is an aminosalicylate that exerts anti-inflammatory effects in the colon via inhibition of prostaglandin and leukotriene synthesis, particularly by blocking cyclooxygenase and lipoxygenase pathways, and by scavenging reactive oxygen species. It also inhibits cytokine production and reduces mucosal inflammation.
5-aminosalicylic acid (5-ASA) inhibits prostaglandin and leukotriene synthesis, reduces neutrophil chemotaxis, and scavenges reactive oxygen species, thereby exerting anti-inflammatory effects on the colonic mucosa.
800 mg orally three times daily or 1600 mg three times daily for 6 weeks; maintenance: 1.6 g daily in divided doses.
Rectal suspension enema: 4 g (60 mL) once daily at bedtime, retained for at least 8 hours. Rectal suppository: 500 mg twice daily (one in the morning and one at bedtime).
None Documented
None Documented
Terminal half-life: 0.6-1.4 hours for 5-ASA; 6-12 hours for N-acetyl-5-ASA. Clinical context: short t1/2 necessitates multiple daily dosing for sustained colonic exposure.
Terminal elimination half-life of mesalamine (5-ASA) is approximately 0.5-2 hours; N-acetyl-5-ASA half-life is 5-10 hours. Rectal administration prolongs local retention without altering systemic half-life.
Renal (80% as 5-ASA and N-acetyl-5-ASA), fecal (20%)
Renal: approximately 78% (primarily N-acetyl-5-ASA and unchanged 5-ASA). Fecal: approximately 20% (unabsorbed drug). Biliary: negligible (<1%).
Category C
Category C
Aminosalicylate
Aminosalicylate